Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.95 INR | +1.27% | -4.08% | +49.63% |
Valuation
Fiscal Period: Maart | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 153.9 | 89.18 | 56.96 | 73.44 | 137.4 | 123.9 |
Enterprise Value (EV) 1 | 151.1 | 82.68 | 38.07 | 48.66 | 91.47 | 72.72 |
P/E ratio | 16.8 x | 16.7 x | 7.56 x | 5.07 x | 29.3 x | 24.6 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 6.14 x | 4.71 x | 1.2 x | 0.88 x | 6.02 x | 4.93 x |
EV / Revenue | 6.03 x | 4.37 x | 0.8 x | 0.58 x | 4.01 x | 2.89 x |
EV / EBITDA | 18.1 x | 13.3 x | 4 x | 2.21 x | 8.93 x | 8.82 x |
EV / FCF | -61.5 x | 45.9 x | 3.2 x | 30.1 x | 4.71 x | 108 x |
FCF Yield | -1.63% | 2.18% | 31.2% | 3.32% | 21.2% | 0.93% |
Price to Book | 5.16 x | 2.54 x | 1.34 x | 1.29 x | 2.23 x | 1.86 x |
Nbr of stocks (in thousands) | 4,996 | 4,996 | 4,996 | 4,996 | 4,996 | 4,996 |
Reference price 2 | 30.80 | 17.85 | 11.40 | 14.70 | 27.50 | 24.80 |
Announcement Date | 8/23/18 | 8/17/19 | 9/7/20 | 9/7/21 | 8/25/22 | 9/7/23 |
Income Statement Evolution (Annual data)
Fiscal Period: Maart | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 25.07 | 18.94 | 47.54 | 83.43 | 22.84 | 25.15 |
EBITDA 1 | 8.359 | 6.236 | 9.522 | 21.99 | 10.24 | 8.246 |
EBIT 1 | 7.853 | 5.45 | 8.944 | 21.41 | 9.315 | 7.31 |
Operating Margin | 31.32% | 28.78% | 18.81% | 25.66% | 40.79% | 29.07% |
Earnings before Tax (EBT) 1 | 7.959 | 2.938 | 7.376 | 22.55 | 9.315 | 9.669 |
Net income 1 | 9.134 | 5.329 | 7.537 | 14.5 | 4.754 | 5.038 |
Net margin | 36.44% | 28.14% | 15.85% | 17.38% | 20.82% | 20.03% |
EPS 2 | 1.828 | 1.067 | 1.509 | 2.902 | 0.9400 | 1.008 |
Free Cash Flow 1 | -2.457 | 1.801 | 11.88 | 1.616 | 19.43 | 0.6758 |
FCF margin | -9.8% | 9.51% | 25% | 1.94% | 85.07% | 2.69% |
FCF Conversion (EBITDA) | - | 28.88% | 124.81% | 7.35% | 189.75% | 8.19% |
FCF Conversion (Net income) | - | 33.79% | 157.67% | 11.15% | 408.7% | 13.41% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 8/23/18 | 8/17/19 | 9/7/20 | 9/7/21 | 8/25/22 | 9/7/23 |
Balance Sheet Analysis
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 2.75 | 6.5 | 18.9 | 24.8 | 45.9 | 51.2 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -2.46 | 1.8 | 11.9 | 1.62 | 19.4 | 0.68 |
ROE (net income / shareholders' equity) | 36% | 16.4% | 19.4% | 29.1% | 8.01% | 7.85% |
ROA (Net income/ Total Assets) | 13.8% | 7.5% | 9.9% | 19.2% | 7.75% | 6.03% |
Assets 1 | 66.38 | 71.03 | 76.15 | 75.51 | 61.32 | 83.57 |
Book Value Per Share 2 | 5.970 | 7.020 | 8.530 | 11.40 | 12.30 | 13.30 |
Cash Flow per Share 2 | 0.0800 | 0.1600 | 0.1000 | 1.050 | 9.180 | 0.0200 |
Capex 1 | 7.77 | 0.01 | 0.01 | 0.02 | 3.06 | 0.26 |
Capex / Sales | 30.99% | 0.04% | 0.01% | 0.02% | 13.38% | 1.05% |
Announcement Date | 8/23/18 | 8/17/19 | 9/7/20 | 9/7/21 | 8/25/22 | 9/7/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- EMMESSA6 Stock
- Financials Emmessar Biotech & Nutrition Limited